Financials
| Faron´s Annual Report 2023 | Mar. 26, 2024 |
| Financial Statement January 1 to December 31 2023 | Mar. 13, 2024 |
| Faron 2023 Half-Year Financial Results | Aug. 29, 2023 |
| Faron´s Annual Report 2022 Published | Mar. 03, 2023 |
| Financial Statement January 1 to December 31 2022 | Mar. 03, 2023 |
| Faron Reports 2022 Half-Year Financial Results | Aug. 25, 2022 |
| Faron´s Annual Report 2021 Published | Mar. 25, 2022 |
Proxies
| Results of the Annual General Meeting | Apr. 05, 2024 |
| Notice of Annual General Meeting 2024 | Mar. 13, 2024 |
| Results of AGM | Mar. 24, 2023 |
| Notice of Faron Pharmaceuticals Ltd’s AGM | Mar. 03, 2023 |
| Results of AGM | Apr. 22, 2022 |
| Notice of Faron Pharmaceuticals Ltd’s AGM | Mar. 25, 2022 |
| Result of AGM | Apr. 23, 2021 |
Ownership Update
| Holding(s) in Company - Replacement | Jun. 25, 2024 |
| Announcement of Placing | Apr. 04, 2024 |
| Grant of options | Dec. 04, 2023 |
| Manager's transactions | Oct. 27, 2023 |
| Exercise of options | Aug. 31, 2023 |
| Grant of Options | Jul. 25, 2023 |
| Holding(s) in Company | Jun. 30, 2023 |
Announcements
| Faron Announces Positive FDA Feedback | Jul. 11, 2024 |
| Update on settlement | Jun. 25, 2024 |
| New shares registered with Finnish Trade Register | Jun. 20, 2024 |
| Fully subscribed EUR 30.7 million share offering | Jun. 20, 2024 |
| Proposed REX Retail Offer | Jun. 05, 2024 |
| Faron commences a share offering | Jun. 04, 2024 |
| Initial positive data from Phase 2 of BEXMAB | May. 20, 2024 |